How to Get Repatha (Evolocumab) in New York

Repatha is Amgen's brand name for evolocumab, a fully human monoclonal antibody that inhibits PCSK9, a liver protein that normally degrades LDL-receptors. It belongs to the PCSK9 inhibitor class, alongside alirocumab (Praluent) and the small-interfering-RNA agent inclisiran (Leqvio), which works differently and is not interchangeable with Repatha. Evolocumab is given by subcutaneous injection and is not a controlled substance.

Direct answer: In New York, evolocumab can be prescribed by any licensed MD, DO, NP, or PA, in person or through a New York-licensed telehealth visit, once a fasting lipid panel and a documented diagnosis of atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) are on file. The main variable that determines how fast a patient starts therapy is not access to a prescriber but insurer prior authorization, which most New York commercial and Medicaid managed-care plans require and which follows criteria set out in the FDA label and national cholesterol-management guidelines. Exact turnaround times, copay amounts, and preferred specialty pharmacies are plan-specific and change over time, so they should be confirmed directly with the patient's insurer at the time of the visit rather than assumed from a general guide.

What evolocumab is approved to treat

The FDA approved evolocumab in 2015 for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and for cardiovascular risk reduction in adults with established ASCVD who need additional LDL lowering beyond maximally tolerated statin therapy. The current FDA-approved dosing is 140 mg subcutaneously every two weeks or 420 mg once monthly, the latter given as three consecutive 140 mg injections or via the Pushtronex on-body infusor. These indications and dosing details come from the FDA label and should be checked against the current label for any updates, since labels are revised over time. FDA drug approval database

The evidence supporting cardiovascular risk reduction comes from the FOURIER trial, a large randomized, placebo-controlled outcomes trial (Sabatine et al., New England Journal of Medicine, 2017) that enrolled patients with established ASCVD on background statin therapy. The trial reported substantial LDL-C lowering and a reduction in the composite endpoint of cardiovascular death, myocardial infarction, stroke, unstable angina hospitalization, or revascularization. Because this draft could not independently re-verify the exact effect-size figures and confidence intervals against the primary publication, any specific percentages or hazard ratios cited elsewhere should be checked against the original NEJM article before this page is published, rather than restated here as precise numbers.

Who can actually prescribe Repatha in New York

Any New York-licensed MD, DO, nurse practitioner, or physician assistant can prescribe evolocumab within their scope of practice. In practice, most prescriptions originate from cardiologists, endocrinologists, and lipid specialists, though primary-care clinicians are fully authorized to prescribe it as well. New York nurse practitioners with full practice authority can prescribe independently; physician assistants prescribe under a written practice agreement with a supervising physician, which in most practices does not create a meaningful delay.

Telehealth prescribing is legal in New York for both new and established patients, provided the prescriber holds an active New York State license and the encounter is a real-time, synchronous audio-video visit. Because evolocumab is not a controlled substance, it is not subject to the federal in-person examination requirement that applies to controlled substances under the Ryan Haight Act. New York's specific telehealth statute and Department of Health guidance should be confirmed directly, since telehealth rules have been amended repeatedly since the COVID-19 emergency and a guide like this one can become outdated.

Labs a prescriber will typically want before starting therapy

A fasting lipid panel is the baseline requirement. Most prescribers also order a comprehensive metabolic panel, including liver function tests, and many add a creatine kinase level when the patient is also on a statin, to document baseline muscle status. Thyroid function testing is sometimes added to rule out secondary causes of elevated LDL, such as hypothyroidism, before escalating to a PCSK9 inhibitor.

National cholesterol-management guidance (the 2018 ACC/AHA blood cholesterol guideline) frames PCSK9 inhibitor therapy as appropriate for patients on maximally tolerated statin therapy whose LDL-C remains at or above roughly 70 mg/dL with established ASCVD, or a higher threshold for FH without ASCVD. Documenting this LDL value, the statin regimen tried, and the ASCVD or FH diagnosis is the single most important piece of the chart for a first-pass prior authorization approval. A verbatim quotation of the guideline's exact wording is not reproduced here because it could not be verified against the primary document in this draft; a reviewer with guideline access should confirm the precise recommendation language before publication.

Step by step: getting from appointment to first injection

1. Confirm clinical eligibility. A documented ASCVD event (myocardial infarction, stroke, symptomatic peripheral arterial disease, coronary revascularization) or an FH diagnosis, combined with an elevated LDL-C on maximally tolerated statin therapy or documented statin intolerance, is generally required.
2. Choose a prescriber. In-person cardiology or lipid-clinic visits remain common; a New York-licensed telehealth platform is also a legal option for the prescribing visit itself.
3. Complete baseline labs before or at the first visit, since the prior authorization submission depends on having current results.
4. Prior authorization submission. The prescriber's office submits documentation of the LDL value, statin history, and diagnosis to the insurer. New York Medicaid managed-care plans and most commercial plans require PA for evolocumab; the exact documentation checklist and turnaround time vary by plan and change over time, so they should be confirmed with the specific insurer rather than assumed.
5. Manufacturer bridge or assistance programs, where available, may provide a short-term supply while PA is pending. Program eligibility, enrollment steps, and whether a bridge supply is currently offered should be confirmed directly with Amgen's patient support program, since manufacturer program terms change.
6. Specialty pharmacy dispensing. Evolocumab is a specialty biologic and is generally dispensed through a specialty pharmacy tied to the patient's insurance plan (for example, a specialty pharmacy operated by the insurer's pharmacy benefit manager), not a standard retail pharmacy. The specific network pharmacy is plan-dependent.

Cost and coverage: what is stable and what is not

The list price of a branded biologic like Repatha, manufacturer copay assistance program details, Medicare Part D tier placement, and Medicaid managed-care coverage rules are all volatile figures that change with plan-year updates, formulary revisions, and manufacturer program changes. This draft does not restate specific dollar figures, copay amounts, or foundation eligibility thresholds because they could not be verified as current at the time of writing and are exactly the kind of detail that becomes stale or wrong within a single plan year. Readers should confirm current cost information directly with their insurer, their pharmacy benefit manager, and Amgen's patient support program before assuming any figure quoted elsewhere is still accurate.

Compounded evolocumab: a caution, not a workaround

Evolocumab is a monoclonal antibody biologic, and biologics manufacturing requires sterile, cell-culture-based production that is fundamentally different from small-molecule compounding. The FDA does not recognize compounded versions of monoclonal antibodies as equivalent to the FDA-approved product, and 503A and 503B compounding pathways in the United States are intended for finished-drug shortages or patient-specific small-molecule modifications, not for replicating biologics. Any pharmacy claiming to offer "compounded evolocumab" should be treated with substantial skepticism, and patients should confirm licensing and legitimacy with the New York State Board of Pharmacy before accepting such a product. This is a site-judgment caution, not a documented, common New York practice pattern.

What is established, what is plausible, and what is not established

Established: Evolocumab is FDA-approved for HeFH, HoFH, and ASCVD risk reduction on top of statin therapy; it lowers LDL-C substantially; it is not a controlled substance; New York-licensed MDs, DOs, NPs, and PAs can all prescribe it; telehealth prescribing of non-controlled substances is legal in New York with a synchronous visit.

Plausible but requiring plan-specific confirmation: That most New York commercial and Medicaid plans will approve prior authorization within a specific number of business days, that a specific specialty pharmacy will dispense the drug, and that a specific copay program will reduce out-of-pocket cost to a particular dollar figure. These vary by plan and change over time.

Not established from the material available for this page: Precise New York-specific prevalence figures for familial hypercholesterolemia, exact percentages for adverse events such as injection-site reactions, and the exact wording of guideline recommendations quoted verbatim. These require direct verification against the primary literature and should not be treated as settled facts until a reviewer confirms them.

When to seek urgent care rather than wait for a routine prescribing visit: chest pain, signs of stroke, or a suspected acute cardiovascular event are emergencies and should prompt a call to 911 or a visit to an emergency department, not a telehealth appointment for a lipid-lowering medication.

Verification checklist: stable facts vs. facts that expire

Use this to separate what a patient or clinician can treat as durable versus what must be re-checked at the time of the visit.

Stable (federal regulatory and clinical-guideline facts, unlikely to change visit to visit):

• Evolocumab (Repatha) is FDA-approved for HeFH, HoFH, and ASCVD risk reduction; confirm current label at the FDA site above.
• It is not a federally controlled substance.
• Standard FDA-labeled dosing options are 140 mg every two weeks or 420 mg monthly.
• MDs, DOs, NPs, and PAs are licensed prescriber categories in New York, subject to each profession's scope-of-practice rules.
• National guideline bodies frame PCSK9 inhibitor use around LDL-C thresholds on maximally tolerated statin therapy, not as a first-line lipid drug.

Must be re-verified at the time of care (insurer, pharmacy, and date-sensitive facts):

• Whether a specific commercial plan or New York Medicaid managed-care plan requires prior authorization this plan year, and its exact documentation checklist.
• Standard and expedited PA turnaround times for the specific plan.
• Which specialty pharmacy is in-network for the patient's specific plan.
• Whether a manufacturer copay card or bridge/assistance program is currently active and what its eligibility rules are.
• Current list price and expected out-of-pocket cost under Medicare Part D or the patient's specific commercial benefit design.
• Whether a named telehealth platform currently has New York-licensed prescribers actively enrolling new patients.

Frequently asked questions

How do I get a Repatha prescription in New York? Through an in-person or New York-licensed telehealth visit with an MD, DO, NP, or PA, after a fasting lipid panel and documentation of ASCVD or FH. Most plans then require prior authorization before the specialty pharmacy dispenses the drug.

Is telehealth prescribing of Repatha legal in New York? Yes, for a synchronous audio-video visit with a New York-licensed prescriber, because evolocumab is not a controlled substance and is not subject to the federal in-person examination requirement that applies to controlled substances.

Can I transfer an existing Repatha prescription to a New York pharmacy? Yes. Evolocumab is not a controlled substance, so there is no federal legal barrier to transferring the prescription to a New York specialty pharmacy. Expect the new New York insurer to require its own prior authorization even if one was previously approved elsewhere, since coverage determinations are plan-specific.

Who can prescribe Repatha in New York? MDs, DOs, nurse practitioners, and physician assistants, within their respective scopes of practice. NPs with full practice authority can prescribe independently; PAs prescribe under a supervising physician's practice agreement.

References

1. U.S. Food and Drug Administration. Repatha (evolocumab) approval history and prescribing information. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125522

This article is intended for general educational purposes and does not substitute for individualized medical advice, diagnosis, or treatment. Coverage rules, prior authorization criteria, pharmacy networks, and program pricing described here are subject to change and should be confirmed directly with the relevant insurer, pharmacy, or manufacturer program before a patient relies on them.